A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub -study SWOG S1400C.

被引：8
|
作者：
Edelman, Martin J.
Redman, Mary Weber
Albain, Kathy S.
McGary, Eric C.
Rafique, Norman
Petro, Daniel P.
Waqar, Saiama Naheed
Miao, Jieling
Griffin, Katie
Papadimitrakopoulou, Vassiliki
Kelly, Karen
Gandara, David R.
Herbst, Roy S.
机构：
[1] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Loyola Univ, Chicago Stritch Sch Med, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA
[4] Kaiser Permanente, Cadillac, CA USA
[5] Tricty Hematol Oncol Associates, Mercy Med Ctr, Massilon, OH USA
[6] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA
[7] Washington Univ, Div Oncol, Dept Med, Sch Med, St Louis, MO USA
[8] Fred Hutchinson Canc Res Ctr, SWOG Stat Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA
[11] Univ Calif Davis, Sacramento, CA 95817 USA
[12] Yale Sch Med, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.9056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9056
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Phase I study of amrubicin (AMR) for patients (pts) with previously treated small cell lung cancer (SCLC)
    Katakami, N.
    Hata, A.
    Yoshioka, H.
    Higashi, Y.
    Nishimura, T.
    Sakaguchi, S.
    Hayashi, M.
    Tomii, K.
    Naya, R.
    Ishihara, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Immune gene expression signatures associated clinical benefit from nivolumab and ipilimumab for previously treated patients with stage IV squamous cell lung cancer: An immune biomarker analysis of phase III SWOG LungMAP S1400I trial
    Duose, Dzifa Y.
    Zhang, Jiexin
    Redman, Mary
    Zhang, Baili
    Cerami, Ethan
    Lindsay, James
    Yu, Joyce
    Biswas, Roshni
    Van Nostrand, Stephen
    Moravec, Radim
    Luthra, Rajyalakshmi
    Al-Atrash, Gheath
    Kelly, Karen
    Herbst, Roy
    Wistuba, Ignacio
    Gettinger, Scott
    Bazhenova, Lyudmila
    Lee, J. Jack
    Zhang, Jianjun
    Haymaker, Cara
    CANCER RESEARCH, 2022, 82 (12)
  • [23] A phase II study of S-1 for previously treated small cell lung cancer (SCLC)
    Kudo, K.
    Ohyanagi, F.
    Horiike, A.
    Miyauchi, E.
    Motokawa, I.
    Horai, T.
    Mun, M.
    Sakao, Y.
    Okumura, S.
    Nakagawa, K.
    Nishio, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small-cell lung cancer (NSCLC)
    Smit, Egbert F.
    Dingemans, Anne-Marie C.
    Groen, Harry J.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S411 - S411
  • [25] A phase II study of erlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small cell lung cancer (NSCLC)
    Groen, H. J.
    Smit, E. F.
    Dingemans, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] A phase II study of eirlotinib (E) and bevacizumab (B) in patients (pts) with previously untreated stage IIIB/IV non-small-cell lung cancer (NSCLC)
    Dingemans, A.
    Groen, H. J. M.
    Smit, E. F.
    EJC SUPPLEMENTS, 2007, 5 (04): : 360 - 360
  • [27] Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study
    Paz-Ares, L.
    Ahn, M-J.
    Felip, E.
    Handzhiev, S.
    Korantzis, I.
    Izumi, H.
    Ohashi, K.
    Majem, M.
    Wolf, J.
    Reck, M.
    Hummel, H-D.
    Blackhall, F.
    Dingemans, A-M. C.
    Owonikoko, T. K.
    Ramalingam, S. S.
    Sands, J.
    Jiang, T.
    Mukherjee, S.
    Anderson, E.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1333 - S1334
  • [28] Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study
    Paz-Ares, L.
    Ahn, M-J.
    Felip, E.
    Handzhiev, S.
    Korantzis, I.
    Izumi, H.
    Ohashi, K.
    Majem Tarruella, M.
    Wolf, J.
    Reck, M.
    Hummel, H-D.
    Blackhall, F.
    Dingemans, A-M. C.
    Owonikoko, T. K.
    Ramalingam, S. S.
    Sands, J.
    Jiang, T.
    Mukherjee, S.
    Anderson, E.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1664 - S1665
  • [29] A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer
    Agelaki, S
    Veslemes, M
    Syrigos, K
    Palamidas, F
    Polyzos, A
    Papakotoulas, P
    Kentepozidis, N
    Milaki, G
    Tzanakis, N
    Kouroussis, C
    Vamvakas, L
    Georgoulias, V
    LUNG CANCER, 2004, 43 (03) : 329 - 333
  • [30] Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
    Kelley, Michael J.
    Jha, Gautam
    Shoemaker, Debra
    Herndon, James E., II
    Gu, Lin
    Barry, William T.
    Crawford, Jeffrey
    Ready, Neal
    CANCER INVESTIGATION, 2017, 35 (01) : 32 - 35
12345